Riskpilot← Back to searchSign inGet full accessOSLO UROLOGISKE KLINIKK AS
ASActiveOrg 920711316Oddenveien 19A, 1363 HøvikSomatiske poliklinikker · NACE 86212Est. 20181 employees
Revenue 2022
NOK 8,5M
+8% vs 2021
EBITDA margin
62.6%
-1% vs 2021
Equity ratio
0.7%
Financial strength
Net profit 2022
NOK 4M
+6% vs 2021
| Revenue | NOK 8,5M | +8% |
| EBITDA | NOK 5,3M | -1% |
| Net profit | NOK 4M | +6% |
| Total assets | NOK 5,7M | +11% |
| Equity | NOK 42K | -98% |
| Employees | 1 | — |
Legal name
OSLO UROLOGISKE KLINIKK AS
Org number
920711316
Legal form
Aksjeselskap
NACE code
86212 · Somatiske poliklinikker
Founded
11. april 2018
Share capital
NOK 30 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Formålet er urologisk behandling, kurs-, foredrags- og undervisningsvirksomhet, utarbeidelse av spesialisterklæringer, sakkyndige oppdrag og konsulentvirksomhet foruten forvaltning av selskapets kapital og ressurser i form av investeringer i eiendom, verdipapirer og andre finansielle instrumenter.
Address
Oddenveien 19A, 1363 Høvik
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 1 315 | 6 220 | 6 946 | 7 835 | 8 492 |
| Staff expenses | −0 | −444 | −837 | −858 | −897 |
| EBITDA | 783 | 4 181 | 4 518 | 5 365 | 5 312 |
| Depreciation & amort. | −150 | −284 | −437 | −432 | −261 |
| EBIT | 633 | 3 897 | 4 081 | 4 933 | 5 051 |
| Net financials | 0 | 0 | 4 | −1 | 24 |
| Profit before tax | 633 | 3 897 | 4 085 | 4 932 | 5 075 |
| Tax | 145 | 857 | 902 | 1 155 | 1 077 |
| Net profit | 489 | 3 040 | 3 183 | 3 777 | 3 998 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 1 578 | 4 266 | 6 857 | 5 172 | 5 723 |
| Equity | 519 | 3 258 | 5 166 | 2 344 | 42 |
| Long-term debt | 891 | 64 | 49 | 55 | −1 |
| Short-term debt | 168 | 944 | 1 642 | 2 774 | 5 683 |
| Total debt | 1 059 | 1 008 | 1 691 | 2 829 | 5 682 |
EBITDA margin
62.6%
This company
15.8%
Market median
+296% vs market
20182022
Equity ratio
0.7%
This company
38.2%
Market median
-98% vs market
20182022
Return on equity
9585.7%
This company
18.4%
Market median
+51996% vs market
20182022
Net profit margin
47.1%
This company
8.1%
Market median
+481% vs market
20182022
Asset turnover
1.48×
This company
1.12×
Market median
+32% vs market
20182022
Debt / equity
136.22×
This company
0.62×
Market median
-21871% vs market
20182022
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JH Chief Executive Officer | Chief Executive Officer | 2018 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2018 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of OSLO UROLOGISKE KLINIKK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jon-Roar Hoff | Chief Executive Officer | 0 companies |
| Siri Foss | Board of Directors | 0 companies |